BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17499597)

  • 1. Exemestane or tamoxifen?
    Atkins CD
    Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499597
    [No Abstract]   [Full Text] [Related]  

  • 2. Exemestane or tamoxifen?
    Ueda M; Toji E; Noda S
    Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499595
    [No Abstract]   [Full Text] [Related]  

  • 3. Switching to aromatase inhibitors in early breast cancer.
    Boccardo F; Rubagotti A
    Lancet; 2007 Feb; 369(9561):533-5. PubMed ID: 17307082
    [No Abstract]   [Full Text] [Related]  

  • 4. Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?
    Hutchinson L
    Nat Clin Pract Oncol; 2004 Nov; 1(1):24-5. PubMed ID: 16264795
    [No Abstract]   [Full Text] [Related]  

  • 5. Cancer: some reasons to be hopeful.
    Lancet; 2007 Feb; 369(9561):531. PubMed ID: 17307079
    [No Abstract]   [Full Text] [Related]  

  • 6. Can switching treatments improve breast-cancer outcome?
    Fricker J
    Lancet Oncol; 2006 Jul; 7(7):536. PubMed ID: 16848012
    [No Abstract]   [Full Text] [Related]  

  • 7. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
    van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
    Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
    Coombes RC; Hall E; Gibson LJ; Paridaens R; Jassem J; Delozier T; Jones SE; Alvarez I; Bertelli G; Ortmann O; Coates AS; Bajetta E; Dodwell D; Coleman RE; Fallowfield LJ; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Stewart A; Stuart N; Snowdon CF; Carpentieri M; Massimini G; Bliss JM; van de Velde C;
    N Engl J Med; 2004 Mar; 350(11):1081-92. PubMed ID: 15014181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant treatment of breast cancer with exemestane.
    Tanvetyanon T
    N Engl J Med; 2004 Jul; 351(1):100-2; author reply 100-2. PubMed ID: 15237463
    [No Abstract]   [Full Text] [Related]  

  • 11. A review of exemestane in the management of breast cancer.
    Wong NS; Pritchard KI
    Expert Opin Pharmacother; 2005 Oct; 6(13):2353-63. PubMed ID: 16218894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
    Aapro M
    Anticancer Drugs; 2008 Mar; 19 Suppl 2():S1. PubMed ID: 18337639
    [No Abstract]   [Full Text] [Related]  

  • 13. [New results of endocrine therapy of breast cancer (the role of Aromasin)].
    Semiglazov VF; Semiglazov VV; Klemtsel' AA; Barash NIu; Zhil'tsova EK; Bozhok AA; Mel'nikova OA; Paltuev RM; Dashian GA; Petrovskiĭ SG; Ivanov VG; Tonuzov EE; Berstein LM
    Vopr Onkol; 2004; 50(6):729-36. PubMed ID: 15755074
    [No Abstract]   [Full Text] [Related]  

  • 14. Switch to exemestane effective in early breast cancer.
    Gourd E
    Lancet Oncol; 2017 Jun; 18(6):e308. PubMed ID: 28506558
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
    Bria E; Carlini P; Cognetti F; Terzoli E; Giannarelli D
    J Natl Cancer Inst; 2007 Jan; 99(2):176; author reply 176-7. PubMed ID: 17228003
    [No Abstract]   [Full Text] [Related]  

  • 16. Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen.
    Pritchard KI
    J Clin Oncol; 2005 Aug; 23(22):4850-2. PubMed ID: 16009956
    [No Abstract]   [Full Text] [Related]  

  • 17. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
    de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
    Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New stars in the sky of treatment for early breast cancer.
    Piccart-Gebhart MJ
    N Engl J Med; 2004 Mar; 350(11):1140-2. PubMed ID: 15014188
    [No Abstract]   [Full Text] [Related]  

  • 19. Exemestane: new preparation. No tangible advance in metastatic breast cancer after tamoxifen failure.
    Prescrire Int; 2001 Aug; 10(54):108-9. PubMed ID: 11718178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intergroup Exemestane Study mature analysis: overall survival data.
    Jassem J;
    Anticancer Drugs; 2008 Feb; 19 Suppl 1():S3-7. PubMed ID: 18340242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.